title: The EPISA study: antimicrobial susceptibility of Staphylococcus aureus causing primary or secondary skin and soft tissue infections in the community in France, the UK and Ireland.
abstract: OBJECTIVE
  To provide information on the susceptibility of Staphylococcus aureus causing skin and soft tissue infections (SSTIs) in France, Ireland and the UK.
  
  
  METHODS
  One thousand three hundred and ninety patients attending their general practitioners for skin infections were recruited. Susceptibility to 11 antimicrobials using CLSI (formerly NCCLS) broth microdilution was determined for 646 S. aureus isolates detected in the evaluable patient population.
  
  
  RESULTS
  Susceptibility results were similar in the UK and Ireland, but differed in France. The largest difference between countries was observed for erythromycin and fusidic acid. In France, 67.8% of isolates were susceptible to erythromycin when compared with 88.6% in Ireland and 92.8% in the UK. However, 93.7% of French isolates were susceptible to fusidic acid, compared with 68.6% in Ireland and 75.6% in the UK. A diagnosis of impetigo was associated with reduced fusidic acid susceptibility.
  
  
  CONCLUSIONS
  Differences in the prevalence of certain diagnoses, particularly impetigo, rather than differences in antibiotic consumption may explain some of the observed differences in susceptibility seen between these countries.
authors.affiliation: Department of Microbiology, Leeds General Infirmary, Great George Street, Leeds, West Yorkshire LS1 3EX, UK. miles.denton@leedsth.nhs.uk
authors.forename: M
authors.initials: M
authors.lastname: Denton
authors.forename: B
authors.initials: B
authors.lastname: O'Connell
authors.forename: P
authors.initials: P
authors.lastname: Bernard
authors.forename: V
authors.initials: V
authors.lastname: Jarlier
authors.forename: Z
authors.initials: Z
authors.lastname: Williams
authors.forename: A Santerre
authors.initials: AS
authors.lastname: Henriksen
mesh_terms: D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003153:Community Health Services / Q000379:methods; D024881:Drug Resistance, Bacterial / Q000187:drug effects* / Q000502:physiology; D005602:France / Q000453:epidemiology; D006801:Humans; D007494:Ireland / Q000453:epidemiology; D018461:Soft Tissue Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology*; D013207:Staphylococcal Skin Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D006113:United Kingdom / Q000453:epidemiology
chemical_list: D000890:Anti-Infective Agents